New research reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional lifestyle regimens.
Research printed in a major medical journal shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such treatments should be aware of the potential of quick rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
That rate of regain implies a return to original mass within about one and a half years.
Analyzing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, compared the results of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through diet and exercise generally experience a more gradual weight regain—around 0.1 kg a month—once they finish.
The Reason for the Rapid Rebound
Doctors believe the way of the jabs accounts for the amplified rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating a significant risk."
An Ongoing Disease?
Medical guidelines suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, due to the significant potential of relapse, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who state that the results "emphasize the persistent character of obesity," akin to managing conditions like high blood pressure.
Patient Experiences
People who have discontinued the medication describe a powerful resurgence of appetite.
"It was like a switch that goes on and I was suddenly ravenous," described one woman.
The struggle is worsened if patients have not adopted permanent dietary or behavioural changes during treatment.
Growing Interest
Figures show that millions of people in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are potent agents for weight loss, they are not a permanent cure and long-term success hinges on integrated behavioural support.
